ClinicalTrials.gg
RecruitingNCT06432868Updated May 29, 2024

Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise

An interventional study of Solarplast (R) and Placebo in Muscle Damage, sponsored by Kent State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Kent State University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are:

Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise?

Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise?

Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery.

Participants will be asked to:

Take Solarplast (R) or placebo daily for 4 weeks

Visit the laboratory at least once per week to receive their supplement

Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.

02

Conditions studied

  • Muscle Damage
03

In context

Lead sponsor

Kent State University is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recreationally-active (participated in at least 2 weight training workouts per week over the previous year) and participates in at least 3h of total structured exercise/week as determined by the health and activity questionnaire.
  • Subject is judged by the Investigator to be healthy and free of any physical limitations (determined by health and activity questionnaire)
  • Subject has a of 18.0-34.9 kg/m2, inclusive
  • Subject is willing to maintain habitual diet throughout the study period
  • Subject is willing to abstain from dietary supplementation throughout the duration of the study.
  • Subject understands the study procedures and signs forms providing to participate in the study and authorization for release of relevant protected health information to the study Investigators

Exclusion criteria

Exclusion Criteria:

  • Subject is currently or will be enrolled in another clinical trial.
  • Subject is a habitual consumer of tea/antioxidants defined as > 8 oz/day of either green or black tea within the 14 days prior to the screening visit.
  • Subject has a history or presence of a cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder.
  • Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  • Subject is unable to perform physical exercise (determined by health and activity questionnaire)
  • Subject is engaged in an extreme diet including but not limited to, Atkins, South Beach, Intermittent Fasting, etc.
  • Subject is allergic to the study product or placebo
  • Subject is taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire)
  • Subject has any chronic illness that causes continuous medical care
  • Taking any type of prescription or over-the-counter medication including but not limited to , non-steroidal anti-inflammatory drugs, and antibiotics within the 14 days prior to the screening visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Active comparator
    Solarplast (R)

    100mg/day of Solarplast (R) supplementation (28 days).

    Dietary Supplement: Solarplast (R)

  • Placebo comparator
    Placebo

    100mg/day of Placebo (maltodextrin (98.8%) and medium chain triglycerides (1.2%)).

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementSolarplast (R)

    Daily supplementation for 28 days prior to heavy resistance exercise.

  • Dietary supplementPlacebo

    Daily supplementation for 28 days prior to heavy resistance exercise.

06

What researchers measure

Primary outcomes

  1. Creatine Kinase Activity

    Marker of Muscle Damage

    Time frame: Acute changes following exercise for 48 hours

Secondary outcomes

  1. Myoglobin Concentration

    Marker of Muscle Damage

    Time frame: Acute changes following exercise for 24 hours

  2. Vertical Jump Height

    Measure of Performance Change

    Time frame: Acute changes following exercise for 48 hours

  3. Mean Squat Velocity

    Measure of Performance Change

    Time frame: Acute changes following exercise for 48 hours

  4. Peak Isometric Muscle Force

    Measure of Performance Change

    Time frame: Acute changes following exercise for 48 hours

  5. Rate of Force Development

    Measure of Performance Change

    Time frame: Acute changes following exercise for 48 hours

  6. Ratings of Perceived Soreness

    Visual Analog Scale (1-100mm; low values indicate reduced soreness)

    Time frame: Acute changes following exercise for 48 hours

  7. Ratings of Perceived Fatigue

    Visual Analog Scale (1-100mm; low values indicated reduced fatigue)

    Time frame: Acute changes following exercise for 48 hours

Other outcomes

  1. Rate of Muscular Fatigue

    Measure of Performance Change

    Time frame: Acute changes following exercise for 48 hours

  2. Rate of Muscular Fatigue

    Measure of Performance Change

    Time frame: Change in Resting Values over 4 weeks of supplementation

  3. Lactate Dehydrogenase Activity

    Marker of Muscle Damage

    Time frame: Acute changes following exercise for 48 hours

  4. Cortisol Concentration

    Circulating Marker of Stress

    Time frame: Acute changes following exercise for 48 hours

  5. Cortisol Concentration

    Circulating Marker of Stress

    Time frame: Change in Resting Values over 4 weeks of supplementation

  6. Glutathione (GSH) Activity

    Circulating Marker of Oxidative Stress

    Time frame: Change in Resting Values over 4 weeks of supplementation

  7. Glutathione (GSH) Activity

    Circulating Marker of Oxidative Stress

    Time frame: Acute changes following exercise for 48 hours

  8. Total Antioxidant Capacity

    Circulating Marker of Oxidative Stress

    Time frame: Change in Resting Values over 4 weeks of supplementation

  9. Total Antioxidant Capacity

    Circulating Marker of Oxidative Stress

    Time frame: Acute changes following exercise for 48 hours

  10. Interleukin 6 (IL-6) Concentration

    Circulating Marker of Inflammation

    Time frame: Change in Resting Values over 4 weeks of supplementation

  11. Interleukin 6 (IL-6) Concentration

    Circulating Marker of Inflammation

    Time frame: Acute changes following exercise for 48 hours

  12. Interleukin 10 (IL-10) Concentration

    Circulating Marker of Inflammation

    Time frame: Change in Resting Values over 4 weeks of supplementation

  13. Interleukin 10 (IL-10) Concentration

    Circulating Marker of Inflammation

    Time frame: Acute changes following exercise for 48 hours

  14. Tumor Necrosis Factor - alpha (TNFa) Concentration

    Circulating Marker of Inflammation

    Time frame: Change in Resting Values over 4 weeks of supplementation

  15. Tumor Necrosis Factor - alpha (TNFa) Concentration

    Circulating Marker of Inflammation

    Time frame: Acute changes following exercise for 48 hours

  16. Rate of Force Development

    Measure of Performance Change

    Time frame: Change in Resting Values over 4 weeks of supplementation

  17. Peak Muscle Force

    Measure of Performance Change

    Time frame: Acute changes following exercise for 48 hours

  18. Vertical Jump Height

    Measure of Performance Change

    Time frame: Change in Resting Values over 4 weeks of supplementation

07

Study locations

1 of 1 sites recruiting
  • Kent State University - Exercise Science & Exercise Physiology
    Kent, Ohio 44242, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06432868
Lead sponsor
Kent State University
Responsible party
Adam Jajtner (Associate Professor, Kent State University) — Principal investigator
First posted
May 29, 2024
Start date
Apr 17, 2024
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
May 29, 2024

Study contacts

Adam R Jajtner, PhD
Contact
ajajtner@kent.edu
330-672-0212 ext. 20212

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion